Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius
The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.
Previous Post
Can AI Assessment of Microcalcifications on Mammography Improve Differentiation of DCIS and Invasive Ductal Carcinoma?
Next Post
Understanding Atopic Dermatitis as an Immune-Mediated Disease
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago